Gut Microbiome-Metabolome Profiling in H. Pylori-SIBO Comorbidity
Key facts
- Who runs it
- Zhongshan Hospital (Xiamen), Fudan University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 42 people enrolled
- Started
- 31 Jan 2024
- Ended
- 28 Feb 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- 13C-Urea Breath Test
- Hydrogen-Methane Breath Test
- Record updated
- 25 March 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Age from 18 to 65 years
- All enrolled patients underwent both the 13C-urea breath test (13C-UBT) and hydrogen-methane breath test (HMBT)
Who cannot take part
- Coexistence of significant concomitant illnesses, including heart disease, renal failure, hepatic disease, previous abdominal surgery, lactation, or pregnancy
- Patients who had used probiotics and antibiotics in the past 12 weeks
- Unwillingness to participate in this study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with concurrent Helicobacter pylori infection and small intestinal bacterial overgrowth (SIBO) represent a clinically challenging subgroup, often experiencing refractory gastrointestinal symptoms and diminished treatment responses. Current evidence indicates that individuals infected with H. pylori may related SIBO as a comorbidity; however, the synergistic effects of these conditions on gut ecosystem homeostasis remain poorly understood. To address this knowledge gap, we employed a dual-omics approach that combined shotgun metagenomic sequencing with liquid chromatography-mass spectrometry (LC-MS) metabolomic profiling. This methodology allowed for a comprehensive mapping of microbial community structures, including species-level taxonomy and functional pathways, as well as host-microbiota co-metabolism signatures in fecal samples.
The 4 groups in the trial
- Group A
H. pylori-positive and SIBO-positive group
Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test
- Group B
H. pylori-negative and SIBO-positive group
Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test
- Group C
H. pylori-positive and SIBO-negative group
Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test
- Group D
H. pylori-negative and SIBO-negative group
Treatment: 13C-Urea Breath Test and Hydrogen-Methane Breath Test
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Characterization of Gut Microbiota and Metabolic Profiles in Patients With Helicobacter Pylori Infection and Small Intestinal Bacterial Overgrowth Based on Metagenomic and Metabolomic Analyses
- Record updated
- 25 March 2026